FORM 4 Check this box if no

longer subject to

Section 16. Form 4 or

Form 5 obligations

may continue. See

Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

OMB APPROVAL OMB 3235-Number: 0287 Estimated average burden hours per 0.5 response...

Transaction(s) (I)

(Instr. 4)

(Instr. 4)

Amount

Number

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Typ	e Response	es)															
1. Name and LEDERM	2. Issuer Name and Ticker or Trading Symbol Tonix Pharmaceuticals Holding Corp. [TNXP]						rp.	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)X Director 10% OwnerX Officer (give title Other (specify below)				elow)					
C/O TON HOLDING AVE., SU	3. Date of Earliest Transaction (Month/Day/Year) 02/09/2015							Chief Executive Officer									
NEW YO	4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person									
(City)	(Sta	Table	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									1					
(Instr. 3) (Month/Day/Year) any						red (A) or See sed of (D) Be 3, 4 and 5) Ov Re		Secur Bene Own Follo Repo	neficially Form: Indicate Direct (D) Indicate Direct (D) Indicate Direct (I)		, , ,		cial				
Common Stock, \$0.0	001 02/09	9/2015			Code	V	Amou 5,000		Price		saction(s) c. 3 and 4)	(Instr. 4)					
par value							-,	1	5.85	5 , -			Dv	Ladan			
Common Stock, \$0.0 par value	001									29,1	67	I	Lal	Leder boratories (1)	,		
Common Stock, \$0.0 par value	001									29,1	67	I	Pha	Starling armaceuti	cals,		
Common Stock, \$0.0 par value	001									184,	628	I	_	Lederma ., LLC (1)			
Common Stock, \$0.0 par value	001									32,4	57	I	Tec	L&L chnologie C (1)	s,		
Common Stock, \$0.001 par value								58,9	72	I	Pha	Targent armaceuti	cals,				
Reminder: R		separate line	for each	class of sec	urities b	enefi	_ `										
							infor requ	matio ired to	n cor resp	ntaine pond ı	d to the col d in this for unless the control nun	rm are not form displa	ays	(1474 9-02)		
		Table l		vative Secu		_		-			ficially Own	ed					
1. Title of	2.	3. Transactio		A. Deemed		4.		, conve 5.			Exercisable	7. Title ar	nd	8. Price of	9. Number of	10.	11. Nature
Derivative Security (Instr. 3)	Conversion	Date	/Year) E	execution D	ate, if	Trans Code	action (. 8)		er an (I	nd Exp	iration Date (Day/Year)	Amount of Underlyin Securities (Instr. 3 a	of ng		Derivative Securities Beneficially Owned Following Reported	Ownership Form of	

Disposed

of (D)

(Instr. 3, 4, and 5)

Date

Expiration

Title

	C1	
Code V (A) (D)	Shares	

Reporting Owners

	Deposition Orange Name / Address	Relationships					
	Reporting Owner Name / Address		10% Owner	Officer	Other		
5	LEDERMAN SETH C/O TONIX PHARMACEUTICALS HOLDING CORP 509 MADISON AVE., SUITE 306 NEW YORK, NY 10022	X		Chief Executive Officer			

Signatures

/s/ Seth Lederman	02/09/2015
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Reporting person may be deemed to be a control person of this entity.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.